Administration of a single dose of lithium ameliorates rhabdomyolysis-associated acute kidney injury in rats

Imagem de Miniatura
Arquivos
art_SHIMIZU_Administration_of_a_single_dose_of_lithium_ameliorates_2023.PDF (2.79 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
Citação
PLOS ONE, v.18, n.2, article ID e0281679, 19p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Rhabdomyolysis is characterized by muscle damage and leads to acute kidney injury (AKI). Clinical and experimental studies suggest that glycogen synthase kinase 3 beta (GSK3 beta) inhibition protects against AKI basically through its critical role in tubular epithelial cell apoptosis, inflammation and fibrosis. Treatment with a single dose of lithium, an inhibitor of GSK3 beta, accelerated recovery of renal function in cisplatin and ischemic/reperfusion-induced AKI models. We aimed to evaluate the efficacy of a single dose of lithium in the treatment of rhabdomyolysis-induced AKI. Male Wistar rats were allocated to four groups: Sham, received saline 0.9% intraperitoneally (IP); lithium (Li), received a single IP injection of lithium chloride (LiCl) 80 mg/kg body weight (BW); glycerol (Gly), received a single dose of glycerol 50% 5 mL/kg BW intramuscular (IM); glycerol plus lithium (Gly+Li), received a single dose of glycerol 50% IM plus LiCl IP injected 2 hours after glycerol administration. After 24 hours, we performed inulin clearance experiments and collected blood / kidney / muscle samples. Gly rats exhibited renal function impairment accompanied by kidney injury, inflammation and alterations in signaling pathways for apoptosis and redox state balance. Gly+Li rats showed a remarkable improvement in renal function as well as kidney injury score, diminished CPK levels and an overstated decrease of renal and muscle GSK3 beta protein expression. Furthermore, administration of lithium lowered the amount of macrophage infiltrate, reduced NF kappa B and caspase renal protein expression and increased the antioxidant component MnSOD. Lithium treatment attenuated renal dysfunction in rhabdomyolysis-associated AKI by improving inulin clearance and reducing CPK levels, inflammation, apoptosis and oxidative stress. These therapeutic effects were due to the inhibition of GSK3 beta and possibly associated with a decrease in muscle injury.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/56317
Referências
  1. Abd-Ellatif RN, 2019, CHEM-BIOL INTERACT, V306, P47, DOI 10.1016/j.cbi.2019.04.008
  2. Abdul AURM, 2018, BIOL OPEN, V7, DOI 10.1242/bio.030874
  3. Al Asmari AK, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0450-8
  4. Alsady M, 2016, J AM SOC NEPHROL, V27, P1587, DOI 10.1681/ASN.2015080907
  5. Bao H, 2019, FASEB J, V33, P14370, DOI 10.1096/fj.201901712R
  6. Bao H, 2014, J AM SOC NEPHROL, V25, P488, DOI 10.1681/ASN.2013040350
  7. Bosch X, 2009, NEW ENGL J MED, V361, P62, DOI 10.1056/NEJMra0801327
  8. Brown CVR, 2004, J TRAUMA, V56, P1191, DOI 10.1097/01.TA.0000130761.78627.10
  9. BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5
  10. Chavez LO, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1314-5
  11. Daher Elizabeth F, 2008, Acta Biomed, V79, P246
  12. de Braganca AC, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12331
  13. Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
  14. Fang CH, 2005, ENDOCRINOLOGY, V146, P3141, DOI 10.1210/en.2004-0869
  15. Fang CH, 2007, AM J PHYSIOL-REG I, V293, pR1545, DOI 10.1152/ajpregu.00244.2007
  16. Findlay AR, 2019, NEUROL-GENET, V5, DOI 10.1212/NXG.0000000000000318
  17. Freland L, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00014
  18. Gois PHF, 2016, FREE RADICAL BIO MED, V101, P176, DOI 10.1016/j.freeradbiomed.2016.10.012
  19. Gonçalves JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107228
  20. Gong RJ, 2016, AM J PHYSIOL-RENAL, V311, pF1168, DOI 10.1152/ajprenal.00145.2016
  21. Homsi E, 2006, KIDNEY INT, V69, P1385, DOI 10.1038/sj.ki.5000315
  22. Homsi E, 1997, RENAL FAILURE, V19, P283, DOI 10.3109/08860229709026290
  23. Homsi E, 2015, AM J PHYSIOL-RENAL, V308, pF1259, DOI 10.1152/ajprenal.00311.2014
  24. Homsi E, 2011, AM J NEPHROL, V33, P49, DOI 10.1159/000322836
  25. Howard C, 2012, KIDNEY INT, V82, P1000, DOI 10.1038/ki.2012.239
  26. HSU CH, 1977, CIRC RES, V40, P178, DOI 10.1161/01.RES.40.2.178
  27. Huerta-Alardín AL, 2005, CRIT CARE, V9, P158, DOI 10.1186/cc2978
  28. Jamadar A, 2020, NEPHRON, V144, P609, DOI 10.1159/000509354
  29. Jones K, 2012, J CLIN INVEST, V122, P4461, DOI 10.1172/JCI64081
  30. Kim JH, 2014, NEPHRON EXP NEPHROL, V128, P21, DOI 10.1159/000365851
  31. Kim JH, 2010, NEPHROL DIAL TRANSPL, V25, P1435, DOI 10.1093/ndt/gfp659
  32. Korrapati MC, 2012, J PHARMACOL EXP THER, V341, P126, DOI 10.1124/jpet.111.190249
  33. Krishnankutty A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09239-5
  34. Lanças T, 2011, RESPIRATION, V82, P177, DOI 10.1159/000326897
  35. Lu ML, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101275
  36. McCullough KR, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.894521
  37. McMahon GM, 2013, JAMA INTERN MED, V173, P1821, DOI 10.1001/jamainternmed.2013.9774
  38. Melli G, 2005, MEDICINE, V84, P377, DOI 10.1097/01.md.0000188565.48918.41
  39. Mirzoev TM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105081
  40. Miyaji T, 2001, J AM SOC NEPHROL, V12, P900, DOI 10.1681/ASN.V125900
  41. Nascimento MM, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.953749
  42. Panizo N, 2015, KIDNEY BLOOD PRESS R, V40, P520, DOI 10.1159/000368528
  43. Pansters NAM, 2015, BBA-MOL BASIS DIS, V1852, P490, DOI 10.1016/j.bbadis.2014.12.006
  44. Pickard BS, 2017, NEUROTHERAPEUTICS, V14, P582, DOI 10.1007/s13311-017-0554-7
  45. Raju NA, 2017, INDIAN J CRIT CARE M, V21, P852, DOI 10.4103/ijccm.IJCCM_186_17
  46. Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169
  47. Sharif S, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.639402
  48. Simpson JP, 2016, EUR J ANAESTH, V33, P906, DOI 10.1097/EJA.0000000000000490
  49. Singh AP, 2012, PHARMACOL REP, V64, P31, DOI 10.1016/S1734-1140(12)70728-4
  50. Soares TD, 2007, LIFE SCI, V81, P647, DOI 10.1016/j.lfs.2007.06.032
  51. Ulusoy S, 2013, AM J NEPHROL, V38, P368, DOI 10.1159/000355537
  52. Wei QQ, 2011, AM J PHYSIOL-RENAL, V301, pF162, DOI 10.1152/ajprenal.00438.2010
  53. Whitley KC, 2020, PHYSIOL REP, V8, DOI 10.14814/phy2.14517
  54. Zahler D, 2022, J CLIN MED, V11, DOI 10.3390/jcm11041137
  55. Zhang DY, 2020, ACS APPL MATER INTER, V12, P56830, DOI 10.1021/acsami.0c17579
  56. Zhang X, 2022, J INORG BIOCHEM, V229, DOI 10.1016/j.jinorgbio.2022.111745
  57. Zhao KL, 2014, MOL MED REP, V10, P3185, DOI 10.3892/mmr.2014.2650
  58. Zhou JH, 2012, THER APHER DIAL, V16, P272, DOI 10.1111/j.1744-9987.2011.01057.x

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/12
Artigos e Materiais de Revistas Científicas - ODS/03